Development of small-molecule agonists against members of the tumor necrosis factor (TNF) receptor superfamily remains a considerable challenge. Presentation of ligand-derived peptides on a trimeric scaffold may point the way toward development of potent small-molecule agonists against this biologically important protein superfamily.
This is a preview of subscription content, log in via an institution to check access.
References
Locksley, R.M., Killeen, N. & Lenardo, M.J. Cell 104, 487–501 (2001).
Steinman, L. Science 305, 212–216 (2004).
Ashkenazi, A. Nat. Rev. Cancer 2, 420–430 (2002).
Gordon, N.C. et al. Biochemistry 42, 5977–5983 (2003).
Livnah, O. et al. Science 273, 464–471 (1996).
Wrighton, N.C. et al. Science 273, 458–464 (1996).
Fournel, S. et al. Nat. Chem. Biol. 1, 366–371 (2005).
Quezada, S.A., Jarvinen, L.Z., Lind, E.F. & Noelle, R.J. Annu. Rev. Immunol. 22, 307–328 (2004).
Karpusas, M. et al. Structure 3, 1031–1039 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hymowitz, S., Ashkenazi, A. Toward small-molecule agonists of TNF receptors. Nat Chem Biol 1, 353–354 (2005). https://doi.org/10.1038/nchembio1205-353
Issue Date:
DOI: https://doi.org/10.1038/nchembio1205-353
- Springer Nature America, Inc.